Millennium: The Takeda Oncology Company – Asian Scientist Magazine

millennium the takeda oncology company

Takeda Initiates Phase 3 Trial For Lung Cancer Drug

Takeda Pharma announced yesterday the initiation of a Phase 3 clinical trial involving 400 patients across Japan, Hong Kong, South Korea, and Taiwan.

Pharma

Millennium Initiates Phase III Trial On Peripheral T-Cell Lymphoma Drug

Millennium today announced the initiation of an international Phase III clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma.

Pharma

Takeda’s Orteronel Enters Phase III Clinical Trials For Prostate Cancer

Takeda has initiated enrollment of patients in Japan for the two ongoing global Phase III clinical trials for its anti-prostate cancer investigational agent, orteronel (TAK-700).

EDITOR’S PICK

Making Precision Medicine Equitable

Researchers and policymakers in Asia are trying to make medical research more inclusive to better serve the region’s diverse communities.
Heart Research Has A Gender Bias

The underrepresentation of women in heart research and treatment has perpetuated the widespread misconception that cardiovascular diseases are more common in men. Some women researchers in Asia have come forward to challenge that.
Nutrition Gets Personal

As more people in Asia use tech to closely regulate what they eat, personalized nutrition is becoming a new normal in the region.

Takeda Initiates Phase 3 Trial For Lung Cancer Drug

Millennium Initiates Phase III Trial On Peripheral T-Cell Lymphoma Drug

Takeda’s Orteronel Enters Phase III Clinical Trials For Prostate Cancer

EDITOR’S PICK

Making Precision Medicine Equitable

Heart Research Has A Gender Bias

Nutrition Gets Personal